Press Releases from 2011
Reinach, Switzerland, 14 December 2011 – Evolva Holding SA (SIX: EVE) today announced that the Russian Patent Office has granted patent protection for EV-077 in the treatment of complications of diabetes for a term extending to 2026. This is the first patent granted covering EV-077. EV-077 patent applications are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Mexico and the USA. Evolva has filed related applications with the aim to extend the protection for its EV-077 portfolio to 2031 and beyond.
Reinach, Switzerland, 8 December 2011 – Evolva Holding SA (SIX: EVE) today announced that Roche (SIX: ROG, RO; OTCQX: RHHBY) has confirmed that Evolva has achieved the second milestone in their collaboration.
Reinach, Switzerland, 15 November 2011 – Evolva Holding SA (SIX: EVE) today announced that the European Commission has approved the use of steviol glycosides in food and beverages in the European Union 1). After the earlier clearance by regulators in the US and many other regions of the world, this marks a major breakthrough in the acceptance of Stevia as a natural, zero-calorie sweetener.
Reinach, Switzerland, 11 November 2011 – Evolva Holding SA (SIX: EVE) announced today that, for personal reasons, Alexandra Santana Sorensen will leave the company as of 29 February 2012. Dr. Sorensen’s responsibilities will be reallocated amongst the existing management team.
Reinach, Switzerland, 7 November 2011 – Evolva Holding SA (SIX: EVE) announced today that it has received regulatory clearance to progress its pharmaceutical compound EV-077 into Phase IIa clinical studies for the treatment of complications of diabetes.
Reinach, Switzerland, 12 September 2011 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 30 June 2011. The condensed accounts are available on Evolva’s website.
Download PDF:
Reinach, Switzerland, 18 August 2011 – Evolva Holding SA (SIX: EVE) announced today that one of the parties to the coordinated sale agreement that was announced by Evolva on December 13, 2010 and extended on May 17, 2011 has given notice of its intention to end its participation in the coordinated sale process.
Reinach, Switzerland, 15 August 2011 – Evolva Holding SA (SIX: EVE), which is active in discovery and development of novel medicines and nutritional ingredients through synthetic biology, announced today that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA Global). Under the terms of the agreement, YA Global has committed to provide up to CHF 30 million in equity financing over a 36 month period in individual advances of up to CHF 600,000 with an initial advance of CHF 500,000. In exchange for the funds to be provided, YA Global will receive Evolva shares. It remains at the sole discretion of Evolva to determine when to draw the advances.
Reinach, Switzerland, 3 August 2011 – Evolva Holding SA (SIX: EVE), which is developing novel medicines and nutritional ingredients through synthetic biology, announced today that Jay Keasling, PhD and Doug Cameron, PhD, both leading experts in the field of synthetic biology and metabolic engineering, have joined the Evolva Scientific Advisory Board.
Reinach, Switzerland, 25 July 2011 – Evolva Holding SA (SIX: EVE), which is developing novel medicines and nutritional ingredients through synthetic biology, announced that data on its lead drug candidate EV-077 were presented in an oral presentation today at the XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Kyoto, Japan. The data suggest that EV-077 might potentiate the in vivo anti-thrombotic efficacy of aspirin in type 2 diabetics with coronary artery disease. The oral presentation was delivered by Dr. Kjell Sakariassen, a prominent expert in this field and member of Evolva’s Clinical Advisory Board.
- 1 of 3
- next ›
Strategy
Products
Legacy Products
Technology
